TRIPLEPOINT VENTURE GROWTH B
TPVGNYSETrading Snapshot
- Day Range
- $4.87 β $4.95
- 52-Week Range
- $4.39 β $6.95
- Volume
- $2.77B
- Avg Volume
- $2.69B
- Shares Outstanding
- 40.6M
- Next Earnings
- Nov 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $97M
- Last Q Revenue
- $24M
- P/E Ratio
- 5.0
- P/S Ratio
- 2.4x
- EPS (TTM)
- $0.95
- Dividend Yield
- 20.08%
- Dilution (1yr)
- +0.9%
Why Investors Own TPVG
- βHigh-growth profile β revenue up +26.4% YoY with expanding US Equity exposure.
- βHealthy economics β 70% gross margin and 9% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
TRIPLEPOINT VENTURE GROWTH B
TPVGAbout TRIPLEPOINT VENTURE GROWTH B
TriplePoint Venture Growth BDC Corp. (TPVG) functions as a business development company, primarily concentrating its investments on growth-stage enterprises backed by venture capital. The firm's core offering involves providing debt financing solutions to companies within the venture growth ecosystem. These solutions encompass a diverse range of products, such as growth capital loans, customized and secured credit facilities, equipment financing, and revolving lines of credit. Additionally, TPVG engages in direct equity investments. Its investment strategy targets companies operating in key sectors, including e-commerce, entertainment, technology, and life sciences. Within the technology sphere, the areas of specific interest are broad, covering cybersecurity, wireless communication equipment, network systems and software, business application software, conferencing solutions, big data analytics, cloud computing, data storage, electronics, energy efficiency, hardware, information services, internet and media, networking, semiconductors, various software categories (including Software-as-a-Service), and other related technological subsectors. For life sciences, TPVG focuses on biotechnology, biofuels/biomass, diagnostic testing and bioinformatics, drug delivery systems, drug discovery, healthcare information systems, healthcare services, medical/surgical/therapeutic devices, pharmaceuticals, and other related fields. The size of TPVG's investments varies based on the type of financing: growth capital loans typically range from $5 million to $50 million, equipment financings are between $5 million and $25 million, and revolving loans generally fall between $1 million and $25 million. Direct equity investments, conversely, are usually from $0.1 million to $5 million, and are structured to not exceed 5% of the portfolio company's total equity. The debt financing instruments are commonly structured as lines of credit, and the company also employs warrants and secured loans in its funding approach. TPVG aims to achieve targeted returns of 10% to 18%. A distinctive aspect of its investment policy is that it does not seek board representation in the companies it finances.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates

TriplePoint Venture Growth BDC (NYSE:TPVG) Insider Sajal Srivastava Sells 313,865 Shares
TriplePoint Venture Growth BDC Corp. (NYSE: TPVG - Get Free Report) insider Sajal Srivastava sold 313,865 shares of TriplePoint Venture Growth BDC stock in a transaction on Friday, September 18th. The shares were sold at

TriplePoint Venture Growth BDC (NYSE:TPVG) CEO James Labe Buys 313,865 Shares of Stock
TriplePoint Venture Growth BDC Corp. (NYSE: TPVG - Get Free Report) CEO James Labe purchased 313,865 shares of the stock in a transaction that occurred on Friday, September 18th. The stock was purchased at an average pri

TriplePoint Venture Growth Offers A High Double-Digit Total Return Potential
TriplePoint Venture Growth (TPVG) stands out by focusing on earlier-stage, high-growth companies rather than the typical middle market BDC approach. I view TPVG as a buy, despite its elevated risk profile and a dividend

Not All Venture Debt Dividend Yields Are Safe: Trinity Capital Vs. TriplePoint Venture
Investor sentiment in venture debt BDCs continues to be shaped by perceived AI-driven risks to software portfolios. TPVG is down 15% over the last year, with TRIN up 13%. TRIN offers an 11.07% annualized yield with month

A Unique Opportunity To Earn Double-Digit Yields From 2 Deeply Discounted BDCs
Since Regulated Investment Companies are legally required to distribute substantially all taxable income, earnings outperformance translates directly into supplemental cash payouts. OBDC generated $0.34 per share in ANII

TriplePoint Venture Growth BDC Q2 Earnings Call Highlights
TriplePoint Venture Growth BDC NYSE: TPVG reported second-quarter results that reflected increased investment activity, continued portfolio repositioning and two monetization events intended to improve liquidity and redu